STOCK TITAN
  1. Home
  2. Sec-filings
  3. RMD
  4. [Form 4] RESMED INC Insider Trading Activity

ResMed Inc. (RMD) CEO exercises 4,991 options and sells 4,991 shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ResMed Inc. Chairman and CEO Michael J. Farrell exercised 4,991 options for ResMed Common Stock at an exercise price of $146.34 per share and acquired the same number of shares on August 7, 2026. He then sold 4,991 shares of ResMed Common Stock at a weighted average price of $205.6895 per share, with individual trades ranging from $202.410 to $204.160. The option exercise and related sale were conducted under a Rule 10b5-1 plan adopted October 31, 2024. Following the option transaction, he held 14,975 ResMed Common Stock options and had an indirect holding of 2,090 ResMed Common Stock shares through the Lisette and Michael Farrell Family Trust.

Positive

  • None.

Negative

  • None.
Insider Farrell Michael J.
Role Chairman and CEO
Sold 4,991 shs ($1.03M)
Approx. gross sale proceeds $1.03M
Approx. exercise cost $730K
Approx. pre-tax spread $296K
Type Security Shares Price Value
Exercise ResMed Common Stock Options F1, F3 4,991 $0.00 $0.00
Exercise ResMed Common Stock F1 4,991 $146.34 $730K
Sale ResMed Common Stock F1, F2 4,991 $205.6895 $1.03M
holding ResMed Common Stock -- -- --
Holdings After Transaction: ResMed Common Stock Options — 14,975 shares (Direct); ResMed Common Stock — 466,256 shares (Direct); ResMed Common Stock — 2,090 shares (Indirect, Lisette and Michael Farrell Family Trust)
Footnotes (3)
  1. F1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
  2. F2. This transaction was executed in multiple trades at prices ranging from $202.410 - $204.160. The price reported above reflects the weighted average sale price.
  3. F3. Represents date options first become exercisable. Options vest 1/3 per year.
Options Exercised 4,991 shares ResMed Common Stock options exercised on August 7, 2026
Option Exercise Price $146.34 per share Conversion or exercise price for 4,991 ResMed options
Shares Sold 4,991 shares ResMed Common Stock sold on August 7, 2026
Weighted Average Sale Price $205.6895 per share Weighted average for multiple trades in the sale transaction
Sale Price Range $202.410–$204.160 per share Range of prices for individual trades in the sale
Options Held After Exercise 14,975 options Total ResMed Common Stock options following the option transaction
Indirect Shares in Family Trust 2,090 shares ResMed Common Stock held indirectly via Lisette and Michael Farrell Family Trust
Option Expiration Date November 21, 2026 Expiration for the exercised ResMed Common Stock options
Rule 10b5-1 plan regulatory
"The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
ResMed Common Stock Options financial
"Security title listed as ResMed Common Stock Options in the transaction table."
indirect ownership financial
"Ownership type marked indirect via Lisette and Michael Farrell Family Trust."

FAQ

What did ResMed (RMD) CEO Michael Farrell report in this Form 4?
Michael J. Farrell reported exercising 4,991 stock options at $146.34 per share and selling 4,991 ResMed Common Stock shares at a weighted average price of $205.6895 per share on August 7, 2026.

Were Michael Farrell’s ResMed (RMD) share transactions under a 10b5-1 plan?
Yes. The filing states the transactions were conducted under a Rule 10b5-1 plan adopted on October 31, 2024, indicating they were pre-arranged rather than discretionary trades based solely on contemporaneous market conditions.

How many ResMed (RMD) options did Michael Farrell exercise and at what price?
He exercised 4,991 ResMed Common Stock options at an exercise price of $146.34 per share. These options first became exercisable on November 11, 2020 and were scheduled to expire on November 21, 2026, vesting one-third per year.

At what prices did Michael Farrell sell his ResMed (RMD) shares?
He sold 4,991 shares of ResMed Common Stock at a weighted average price of $205.6895 per share. The sales were executed in multiple trades with prices ranging from $202.410 to $204.160 per share, according to the filing footnote.

What ResMed (RMD) holdings does Michael Farrell report after these transactions?
After exercising options, he held 14,975 ResMed Common Stock options related to this grant. The filing also reports 2,090 ResMed Common Stock shares held indirectly through the Lisette and Michael Farrell Family Trust as of the reported date.

What is the vesting schedule of the ResMed (RMD) options Michael Farrell exercised?
The footnote explains the options first became exercisable on November 11, 2020 and vest 1/3 per year. These options were scheduled to expire on November 21, 2026, defining the window during which they could be exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Farrell Michael J.
(Last)(First)(Middle)
RESMED INC.
9001 SPECTRUM CENTER BLVD
(Street)
SAN DIEGO CALIFORNIA 92123
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairman and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
ResMed Common Stock08/07/2026M(1)4,991A$146.34471,247D
ResMed Common Stock08/07/2026S(1)4,991D$205.6895(2)466,256D
ResMed Common Stock2,090ILisette and Michael Farrell Family Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
ResMed Common Stock Options$146.3408/07/2026M(1)4,99111/11/2020(3)11/21/2026ResMed Common Stock4,991$014,975D
Explanation of Responses:
1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
2. This transaction was executed in multiple trades at prices ranging from $202.410 - $204.160. The price reported above reflects the weighted average sale price.
3. Represents date options first become exercisable. Options vest 1/3 per year.
/s/ Michael J. Farrell, Chairman and CEO08/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR